Novel Therapeutics for Management of Lupus Nephritis: What Is Next?

Thakare, Sayali; So, Paolo Nikolai; Rodriguez, Sonia; Hassanein, Mohamed; Lerma, Edgar V.; Wiegley, Nasim

doi:10.1016/j.xkme.2023.100688

Cited by 3 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, the urine and serum MCP-1 levels noted in the non-proliferative group were 544.47 ± 430.63 pg/ml creatinine and 200.40 ± 171.83 pg/mL creatinine, correspondingly ( 65 ). The non-selective immunosuppressive drugs utilized in the clinical management of proliferative LN are associated with significant adverse effects ( 66 ). In an attempt to identify a more targeted therapeutic agent with comparable efficacy but reduced side effects, one study focused on inhibiting MCP-1 and the homeostatic chemokine stromal cell-derived factor-1 (SDF-1/CXCL12).…”

Section: Mcp-1 As a Biomarkermentioning

confidence: 99%

Role of MCP-1 as an inflammatory biomarker in nephropathy

Liu,

Xu,

Xiang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

The Monocyte chemoattractant protein-1 (MCP-1), also referred to as chemokine ligand 2 (CCL2), belongs to the extensive chemokine family and serves as a crucial mediator of innate immunity and tissue inflammation. It has a notable impact on inflammatory conditions affecting the kidneys. Upon binding to its receptor, MCP-1 can induce lymphocytes and NK cells’ homing, migration, activation, differentiation, and development while promoting monocytes’ and macrophages’ infiltration, thereby facilitating kidney disease-related inflammation. As a biomarker for kidney disease, MCP-1 has made notable advancements in primary kidney diseases such as crescentic glomerulonephritis, chronic glomerulonephritis, primary glomerulopathy, idiopathic proteinuria glomerulopathy, acute kidney injury; secondary kidney diseases like diabetic nephropathy and lupus nephritis; hereditary kidney diseases including autosomal dominant polycystic kidney disease and sickle cell kidney disease. MCP-1 not only predicts the occurrence, progression, prognosis of the disease but is also closely associated with the severity and stage of nephropathy. When renal tissue is stimulated or experiences significant damage, the expression of MCP-1 increases, demonstrating a direct correlation with the severity of renal injury.

show abstract

Section: Mcp-1 As a Biomarkermentioning

confidence: 99%

Role of MCP-1 as an inflammatory biomarker in nephropathy

Liu,

Xu,

Xiang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Необходимо провести дополнительные исследования для таких специфических ситуаций, как мембранозный ВН, возникший в детском возрасте, поддерживающая терапия и синдром антифосфолипидных антител. Прецизионная медицина, подбор лекарственного средства в соответствии с фенотипом заболевания, на которое оно в наибольшей степени отвечает, является будущим в лечении ЛН и СКВ (например, анифролумаб у больных СКВ с высоким уровнем интерферона) [1][2][3][4][5][6][7][8][9][10][11].…”

Section: индукционная терапия пролиферативного вн Kdigo 2012unclassified

LUPUS NEPHRITIS: CLINICAL CASE WITH DOUBLE TRANSPLANTATION. Ar.A. DEMIN’S CONTRIBUTION TO STUDYING THE DISEASE

Demin

2023

SMV

View full text Add to dashboard Cite

Introduction. Lupus nephritis (LN) is common in systemic lupus erythematosus (SLE), a severe autoimmune disease with a poor prognosis. Restoring the immune system and self-tolerance using high-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation (AHSCT) is a new approach in the treatment of refractory SLE. The effectiveness of SLE with LN treatment in the long-term follow-up should be the subject for study. Methods. Patient I., 25 years old, with refractory SLE and LN is described. Standard therapy was ineffective, the SLEDAI score remained 22 points, so the patient underwent high-dose immunosuppressive therapy (HIT) with ASCT, and she was included in the registry of the European Group for Blood and Marrow Transplantation of the European League Against Rheumatism (EBMT/EULAR). Results. As a result of ASCT, complete clinical and serological remission was achieved (score on the SLEDAI scale – 0 points) for 3 years. Then there was a relapse with nephrotic syndrome and anti-DNA positivity which led to the end-stage renal failure. Despite therapy, the disease activity persisted, and the patient was on regular hemodialysis for 1 year, then underwent allogeneic kidney transplantation. Currently, 18 years have passed since HIT and AHSCT and 11 years since renal transplantation. The patient receives standard post-transplant immunosuppression, and her condition remains stable, the renal allograft is functioning, the SLEDAI score is 2 points (low titer anti-DNA positivity). Discussion. Modern standards of chemotherapy (hydroxychloroquine, mycophenolate mofetil, cyclophosphamide, corticosteroids), bioactive immunotherapy (rituximab, belimumab, obinituzumab, anifrolumab), “multi-target therapy” (standard + tacrolimus, voclosporin, mycophenolate mofetil), and new approaches (immuno- and nephrotransplantation) for lupus nephritis. Conclusion. The successful long-term results of the first case of immunoablation with high-dose immunosuppressive therapy and double autologous stem cell and allogeneic kidney transplantation for SLE with refractory lupus nephritis and an analysis of the effectiveness of modern treatment approaches are presented.

show abstract

In the Pursuit of Precision: Novel Target Therapies Revolutionizing SLE Care

Velikova,

Miteva,

Kokudeva

et al. 2024

Rheumato

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a chronic, autoimmune, immune complex-mediated disease affecting mainly females at a young age. The disease etiology is still unknown, and different genetic and epigenetic factors related to disease onset and manifestations are being explored. The standard treatment regimen for SLE includes the long-term use of corticosteroids and non-specific immunosuppressive agents, often limited by co-morbidities or related side effects. However, recent advances in disease pathogenesis clarifying the role of inflammatory cytokines, chemokines, immune cells, and co-stimulation molecules have made a more practical, targeted approach possible, leading to personalized treatment strategies. This review summarizes current knowledge about SLE-targeted therapies in clinical practice.

show abstract

Novel Therapeutics for Management of Lupus Nephritis: What Is Next?

Cited by 3 publications

References 36 publications

Role of MCP-1 as an inflammatory biomarker in nephropathy

Role of MCP-1 as an inflammatory biomarker in nephropathy

LUPUS NEPHRITIS: CLINICAL CASE WITH DOUBLE TRANSPLANTATION. Ar.A. DEMIN’S CONTRIBUTION TO STUDYING THE DISEASE

In the Pursuit of Precision: Novel Target Therapies Revolutionizing SLE Care

Contact Info

Product

Resources

About